Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nadifloxacin→

Nadifloxacin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
124858-35-1
Molecular formula
C19H21FN2O4
Molecular weight
360.4 g/mol
Drug class
Topical fluoroquinolone antibacterialDNA gyrase and topoisomerase IV inhibitor
Mechanism of action
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. It has activity against a range of Gram-positive and Gram-negative skin pathogens, including Cutibacterium acnes and Staphylococcus aureus.
Indications / reported uses
  • Topical treatment of acne vulgaris and selected superficial bacterial skin infections caused by susceptible organisms in markets where nadifloxacin is authorised.

Sources: https://www.tandfonline.com/doi/full/10.1586/17469872.1.5.643 · https://bertin-bioreagent.cvmh.fr/nadifloxacin/ · https://daneenpharma.com/nadif/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nadifloxacin Environmental Risk Assessment (ERA) (the Nadifloxacin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.